USPTO Examiner KENYON JOHN S - Art Unit 1625

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18827512CRYSTALLINE FORMS OF A MENIN INHIBITORSeptember 2024June 2025Allow920NoNo
18783334CYCLOPROPANE SKELETON MONOPHOSPHINE LIGANDS, PALLADIUM COMPLEXES THEREOF, PREPARATION METHODS AND APPLICATIONJuly 2024March 2025Allow801NoNo
18591732SUBSTITUTED THIOPHENECARBOXAMIDES AND ANALOGUES AS ANTIBACTERIALS AGENTSFebruary 2024May 2025Allow1501NoNo
18427924N'-(2-(5-(4-CHLOROPHENYL)-1,3,4-OXADIAZOL-2-YLTHIO)ACETOXY)-1-NAPHTHIMIDAMIDE AS AN ANTIMICROBIAL COMPOUNDJanuary 2024April 2024Allow300NoNo
18293947UREA AND MELAMINE PRODUCTIONJanuary 2024September 2024Allow710NoNo
18395377N'-(2-(5-(4-CHLOROPHENYL)-1,3,4-OXADIAZOL-2-YLTHIO)ACETOXY)-2-NAPHTHIMIDAMIDE AS AN ANTIMICROBIAL COMPOUNDDecember 2023March 2024Allow310NoNo
18490700COMPOSITIONS AND METHODS FOR TREATING CANCEROctober 2023June 2024Allow711YesNo
18486813N'-(1-NAPHTHOYLOXY)-2-(BENZO[D]OXAZOL-2-YL)ACETIMIDAMIDE AS AN ANTIMICROBIAL COMPOUNDOctober 2023January 2024Allow301NoNo
184869212-ALKOXY[4,3:6,2-TERPYRIDINE]-3-CARBONITRILE AS ANTIMICROBIAL COMPOUNDSOctober 2023January 2024Allow300NoNo
18378785N'-(2-(5-(4-CHLOROPHENYL)-1,3,4-OXADIAZOL-2-YLTHIO)ACETOXY)-1-NAPHTHIMIDAMIDE AS AN ANTIMICROBIAL COMPOUNDOctober 2023March 2024Allow511NoNo
18379024N'-(2-(5-(4-CHLOROPHENYL)-1,3,4-OXADIAZOL-2-YLTHIO)ACETOXY)-2-NAPHTHIMIDAMIDE AS AN ANTIMICROBIAL COMPOUNDOctober 2023January 2024Allow301NoNo
18470331Compositions of Clofazimine, Combinations Comprising Them, Processes for Their Preparation, Uses and Methods Comprising ThemSeptember 2023June 2025Allow2111NoNo
18461093SULFONE PYRIDINE ALKYL AMIDE-SUBSTITUTED HETEROARYL COMPOUNDSSeptember 2023March 2025Allow1811NoNo
18221546SYNTHESIS OF HETEROCYCLIC COMPOUNDSJuly 2023June 2025Allow2311NoNo
18217874SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAMEJuly 2023December 2024Allow1711YesNo
18211772PROCESSES FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATORJune 2023February 2024Allow800NoNo
18325214PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF CARBAPROSTACYCLIN ANALOGUESMay 2023October 2024Allow1711NoNo
18195142COMPOSITIONS AND METHODS FOR OPIOID ANTAGONIST DELIVERYMay 2023November 2023Allow610YesNo
18043987PHOSPHONATE PRODUCTS AND METHODSMarch 2023November 2024Allow2011NoNo
18090722SYSTEMS AND METHODS FOR INCREASING STABILITY OF DRONABINOL COMPOSITIONSDecember 2022February 2025Allow2521NoNo
18089065HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORSDecember 2022May 2024Abandon1701NoNo
18070827PROCESS FOR SYNTHESIS OF 2-AMINO-5-CHLORO-N-,3-DIMETHYLBENZAMIDENovember 2022June 2024Allow1811NoNo
18058655COMPOSITIONS AND METHODS FOR TREATING CANCERNovember 2022October 2023Allow1011NoNo
17992049Heterocyclic Compounds as RET Kinase InhibitorsNovember 2022December 2024Abandon2511NoNo
17991558THERAPEUTICS FOR THE TREATMENT OF GLAUCOMANovember 2022September 2024Allow2210NoNo
17990939SYNTHETIC PROCESS AND NOVEL INTERMEDIATESNovember 2022March 2024Abandon1601NoNo
18053197HYDROCHLOROTHIAZIDE COMPOSITIONSNovember 2022November 2023Allow1221NoNo
17972220METHODS FOR THE SYNTHESIS OF ACTIVATED ETHYLFUMARATES AND THEIR USE AS INTERMEDIATESOctober 2022September 2024Allow2211NoNo
18047289COMPOSITIONS COMPRISING CIPROFLOXACIN AND CELECOXIBOctober 2022June 2024Allow2001NoNo
17960046HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASESOctober 2022August 2024Allow2221NoNo
17913883STABLE HEAVY ISOTOPES IN AMIDE FUNCTIONAL GROUPS AND USES THEREOFSeptember 2022March 2025Allow3011NoNo
17950902Pharmaceutical Formulations Containing Relacorilant, a Heteroaryl-Ketone Fused Azadecalin CompoundSeptember 2022December 2023Allow1511NoNo
17946635Cannabinoid Product for Improvement of SleepSeptember 2022January 2025Abandon2801NoNo
17929027PREPARATION OF A P2X3 ANTAGONISTAugust 2022May 2025Allow3300NoNo
17884154TERNARY PHOTOACTIVE LAYER COMPOSITION AND ORGANIC SOLAR CELL COMPRISING SAMEAugust 2022June 2025Allow3401NoNo
17858917HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERSJuly 2022September 2024Allow2621NoNo
17810214SUBSTITUTED THIOPHENECARBOXAMIDES AND ANALOGUES AS ANTIBACTERIALS AGENTSJune 2022December 2023Allow1701NoNo
17806395SYNTHESIS OF FMOC-PROTECTED MORPHOLINO MONOMERS AND OLIGOMERSJune 2022April 2024Allow2221NoNo
17804566PROTEIN-TARGETING COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONSMay 2022October 2024Abandon2921NoNo
17742843Solid Oral Dosage Forms Of DexamethasoneMay 2022December 2023Abandon1901NoNo
17739099NAIL HARDENING COMPOSITION AND METHOD OF USEMay 2022December 2022Allow711NoNo
17737273PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF CARBAPROSTACYCLIN ANALOGUESMay 2022September 2023Allow1601NoNo
17737408MULTI-STAGE ESTERIFICATION PROCESSMay 2022October 2023Abandon1801NoNo
17737113PHENYL AND PYRIDINYL SUBSTITUTED IMIDAZOLES AS MODULATORS OF RORgTMay 2022July 2023Abandon1501NoNo
17736644PROCESS FOR PRODUCING 2,5-FURANDICARBOXYLIC ACID DIALKYL ESTERMay 2022July 2023Abandon1501NoNo
17736688FLUORESCENT DYES CONTAINING BIS-BORON FUSED HETEROCYCLES AND USES IN SEQUENCINGMay 2022March 2024Allow2211NoNo
17755398Ion Channel Antagonists/Blockers and Uses ThereofApril 2022September 2024Allow2821YesNo
17729287PROCESS FOR THE PRODUCTION OF FURFURAL USING A WATER IMMISCIBLE ORGANIC SOLVENTApril 2022August 2023Abandon1511NoNo
17724717METHODS AND FORMULATIONS FOR REDUCING BOVINE EMISSIONSApril 2022November 2023Allow1911NoNo
17659736DECARBOXYLATED CANNABIS COMPOSITIONS AND METHODS OF MAKING THE SAMEApril 2022November 2023Allow1901NoNo
17722832ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDSApril 2022April 2024Allow2411YesNo
17722654METHOD FOR PRODUCING ORGANOMETALLIC COMPOUND AND THIN FILM FABRICATED USING ORGANOMETALLIC COMPOUND OBTAINED THEREBYApril 2022April 2024Allow2411NoNo
17721781EFFICIENT NEW PROCESS FOR SYNTHESIS OF 2-AMINO-5-CHLORO-N-,3-DIMETHYLBENZAMIDEApril 2022October 2022Allow601NoNo
17721133Synthesis And Characterization Of Air-Stable Iron-Based Catalysts For Suzuki-Miyaura Cross-Coupling Reactions Of Alkyl Halides And Aryl Boronic EstersApril 2022April 2024Allow2421NoNo
17719727FUNCTIONALIZED NANOPARTICLES AND THEIR USE IN TREATING BACTERIAL INFECTIONSApril 2022April 2024Allow2411NoNo
17715366COT MODULATORS AND METHODS OF USE THEREOFApril 2022July 2023Allow1510NoNo
17701872FERROPTOSIS INDUCING COMPOUND, COMPOSITIONS COMPRISING THE SAME, AND METHODS OF INDUCING FERROPTOSISMarch 2022November 2023Allow2021NoNo
17698527METHODS AND COMPOSITIONS FOR THE TREATMENT OF SHIGA TOXICOSISMarch 2022July 2023Abandon1601NoNo
17694910Cannabinoid Product for Control of Pre-diabetic MarkersMarch 2022July 2023Abandon1601NoNo
17694287DIRECT SYNTHESIS OF CYCLIC CARBONATES USING CHOLINE CHLORIDE AS CATALYST UNDER MILD CONDITIONSMarch 2022October 2023Allow1901NoNo
17692026INHIBITORS OF KRAS G12C AND METHODS OF USING THE SAMEMarch 2022January 2024Allow2211NoNo
17689925SYNTHESIS AND USE OF OXA-SPIRODIPHOSPHINE LIGANDMarch 2022April 2024Allow2621NoNo
17688101POLYCYCLIC CARBOGENIC MOLECULES AND USES THEREOF AS ANTI-CANCER AGENTSMarch 2022January 2024Allow2211NoNo
17687002ION CHANNEL MODULATORSMarch 2022February 2024Allow2311NoNo
17587555MK2 INHIBITORS, THE SYNTHESIS THEREOF, AND INTERMEDIATES THERETOJanuary 2022March 2024Allow2621YesNo
17584590Choline Salt Forms of an HIV Capsid InhibitorJanuary 2022July 2023Allow1811NoNo
17584533SOLID FORMS OF AN HIV CAPSID INHIBITORJanuary 2022July 2023Allow1811NoNo
17629543DIFLUOROHALOALLYLAMINE SULFONE DERIVATIVE INHIBITORS OF LYSYL OXIDASES, METHODS OF PREPARATION, AND USES THEREOFJanuary 2022June 2025Abandon4111NoNo
17574998Antibacterial Activity of Functionalized DihydropyrimidinesJanuary 2022February 2024Allow2511NoNo
17567201SELECTIVE SMALL MOLECULE PEPTIDOMIMETIC MELANOCORTIN LIGANDSJanuary 2022November 2023Allow2221NoNo
17564418AMORPHOUS SOLID DISPERSION FORMULATIONDecember 2021October 2023Allow2211NoNo
17556827ORGANIC COMPOUND, ORGANIC LIGHT-EMITTING ELEMENT, DISPLAY APPARATUS, PHOTOELECTRIC CONVERSION APPARATUS, ELECTRONIC APPARATUS, ILLUMINATION APPARATUS, MOVING OBJECT, AND EXPOSURE LIGHT SOURCEDecember 2021October 2023Allow2211YesNo
17553856HYBRID POLYVINYL ALCOHOL/ LINSEED DUAL CROSSLINKED NANOCOMPOSITE HYDROGEL LOADED WITH DOXYCYCLINE FOR THE PRODUCTION OF ACNE PATCHESDecember 2021October 2024Allow3431NoNo
17644604METHODS TO DETERMINE KDM1A TARGET ENGAGEMENT AND CHEMOPROBES USEFUL THEREFORDecember 2021September 2024Allow3311NoNo
17549289COMPOSITIONS COMPRISING UROLITHINS AND USES THEREOF FOR THE STIMULATION OF INSULIN SECRETIONDecember 2021July 2023Abandon1901NoNo
17546175HYDROCHLOROTHIAZIDE COMPOSITIONSDecember 2021September 2023Abandon2101NoNo
17545053DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND FOOD WITH FUNCTION CLAIMSDecember 2021September 2024Allow3321NoNo
17543038PROCESS FOR THE PREPARATION OF UNSATURATED CARBOXYLIC ACIDS BY CARBONYLATION OF ALLYL ALCOHOLS AND THEIR ACYLATION PRODUCTSDecember 2021July 2023Abandon1901NoNo
17534764ANTI-VIRAL ACTIVITY OF VPS34 INHIBITORSNovember 2021October 2024Abandon3521NoNo
17533592(AZA)Benzothiazolyl Substituted Pyrazole CompoundsNovember 2021September 2024Abandon3401NoNo
17532712BORATE ESTER COMPLEXES OF A-HYDROXY CARBOXYLIC ACIDS AND THEIR CONJUGATE BASE BUFFERSNovember 2021February 2025Allow3931YesNo
17522866Process for production of essentially pure delta-9-tetrahydrocannabinolNovember 2021January 2024Allow2621YesNo
17609135DHODH INHIBITORS AND THEIR USE AS ANTIVIRAL AGENTSNovember 2021November 2023Abandon2401NoNo
17514387Cannabinoid Product for Assistance with Weight LossOctober 2021July 2023Abandon2101NoNo
17502975USE OF SMALL MOLECULE INHIBITORS OF THE BFRB:BFD INTERACTION IN BIOFILMSOctober 2021November 2024Allow3711NoNo
17500070Trytophan Metobolic Stimulation CompositionsOctober 2021September 2023Allow2411NoNo
17450205FORMULATION OF A PAN-JAK INHIBITOROctober 2021June 2023Allow2001NoNo
17601085PHENYLMETHYLPYRAZOLONE COMPOUND HAVING A NOVEL CRYSTAL FORM, AND METHOD FOR PRODUCING SAMEOctober 2021April 2025Abandon4201NoNo
17492282Pyrazolo[1,5-A][1,3,5]Triazine and Pyrazolo[1,5-A]Pyrimidine Derivatives as CDK InhibitorsOctober 2021December 2024Abandon3831NoNo
17487279Histone Deacetylase Inhibitors and Methods of Use ThereofSeptember 2021December 2023Abandon2711NoNo
17598707QUINOLINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCERSeptember 2021January 2025Abandon3901NoNo
17479869USE OF TACROLIMUS IN PREPARATION OF MEDICAMENT FOR INITIATING TISSUE REGENERATION FUNCTIONSeptember 2021January 2024Allow2811NoNo
17437192FUSED RING SUBSTITUTED AROMATIC COMPOUND AND PREPARATION METHOD THEREFOR, HERBICIDAL COMPOSITION, AND USE THEREOFSeptember 2021June 2025Allow4511NoNo
17467974METHOD FOR PURIFICATION OF TERPENOID AMINO ALCOHOL DERIVATIVESSeptember 2021June 2023Allow2101NoNo
17435181METHOD FOR PREPARING TRICYCLIC COMPOUND, AND INTERMEDIATE THEREOFAugust 2021April 2025Abandon4301NoNo
17407276AMINE-BORANES AS BIFUNCTIONAL REAGENTS FOR DIRECT AMIDATION OF CARBOXYLIC ACIDSAugust 2021April 2024Allow3221NoNo
17405767PHYTONADIONE COMPOSITIONS AND RELATED METHODSAugust 2021April 2024Allow3211NoNo
17397457METHODS AND RELATED TOOLS FOR CBD CONVERSION TO THCAugust 2021November 2024Allow4021NoNo
17396717RIMEGEPANT FOR CGRP RELATED DISORDERSAugust 2021March 2023Abandon2011NoNo
17426931SOLID STATE FORMS OF OCLACITINIB MALEATEJuly 2021September 2024Allow3710NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner KENYON, JOHN S.

Strategic Value of Filing an Appeal

Total Appeal Filings
13
Allowed After Appeal Filing
6
(46.2%)
Not Allowed After Appeal Filing
7
(53.8%)
Filing Benefit Percentile
72.8%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 46.2% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.

Strategic Recommendations

Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Examiner KENYON, JOHN S - Prosecution Strategy Guide

Executive Summary

Examiner KENYON, JOHN S works in Art Unit 1625 and has examined 810 patent applications in our dataset. With an allowance rate of 78.5%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 24 months.

Allowance Patterns

Examiner KENYON, JOHN S's allowance rate of 78.5% places them in the 39% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.

Office Action Patterns

On average, applications examined by KENYON, JOHN S receive 1.56 office actions before reaching final disposition. This places the examiner in the 40% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by KENYON, JOHN S is 24 months. This places the examiner in the 70% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +25.7% benefit to allowance rate for applications examined by KENYON, JOHN S. This interview benefit is in the 76% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 33.2% of applications are subsequently allowed. This success rate is in the 65% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 58.4% of cases where such amendments are filed. This entry rate is in the 81% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 92% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 85% percentile among all examiners. Of these withdrawals, 90.9% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 57.9% are granted (fully or in part). This grant rate is in the 74% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.9% of allowed cases (in the 66% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).

Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.5% of allowed cases (in the 68% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • Request pre-appeal conferences: PACs are highly effective with this examiner. Before filing a full appeal brief, request a PAC to potentially resolve issues without full PTAB review.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.